磷酸二酯酶2对抑郁焦虑及认知障碍等中枢神经疾病的调节作用

摘要/Abstract

摘要： 磷酸二酯酶(Phosphodiesterase,PDE)水解细胞内第二信使-环磷酸腺苷和环磷酸鸟苷,降低细胞内第二信使的含量,进而影响下游信号转导,调节细胞内的生命活动。磷酸二酯酶2(PDE2)是磷酸二酯酶大家族的成员之一,在中枢神经系统中分布广泛,尤其在海马和杏仁核部分密集,近年来越来越多的研究表明PDE2可能参与中枢神经系统疾病的调节,而相应的PDE2抑制剂可能具有治疗抑郁、焦虑和学习记忆障碍等中枢神经系统疾病前景。本文综述了PDE2在中枢神经系统疾病调节中的作用及其抑制剂在治疗相关疾病的应用。

关键词: 磷酸二酯酶2, 环磷酸腺苷, 环磷酸鸟苷, 中枢神经系统, 学习记忆, 抑郁焦虑

Abstract: Cyclic nucleotide Phosphodiesterases (PDEs) are the only known enzymes that catalyze the hydrolysis of cyclic AMP (cAMP) and cyclic GMP (cGMP) and thus are integral to the regulation of cyclic nucleotide signaling and cellular communication. PDE2 is a member of the super family and it is highly expressed in the limbic nervous system, including the amygdala, hippocampus, and hypothalamus, which are important for emotional and cognitive function. This review discusses the current state and future development in the burgeoning field of PDE2 in the central nervous system. It is becoming increasingly clear that PDE inhibitors have therapeutic potential for the treatment of neuropsychiatric disorders involving disturbances of mood, emotion, and cognition.

Key words: PDE2, cAMP, cGMP, CNS, Learning and memory, Anxiety and depression

中图分类号:

R741

严伟, 陈玲, 王飞, 李晴宇, 牛国忠. 磷酸二酯酶2对抑郁焦虑及认知障碍等中枢神经疾病的调节作用[J]. 中国临床药理学与治疗学, 2013, 18(12): 1424-1429.

YAN Wei, CHEN Ling, WANG Fei, LI Qing-yu, NIU Guo-zhong. Phosphodiesterases in the CNS:Implications in mood and cognitive disorders[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1424-1429.

参考文献

[1] Conti M, Richter W, Mehats C, et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling[J]. J Biol Chem, 2003,278 (8): 5493-5496.
[2] Greengard P. The neurobiology of slow synaptic transmission[J]. Science, 2001,294 (5544): 1024-1030.
[3] Lesch KP, Lerer B. The 5-HT receptor-G-protein-effectorsystem complex in depression. Effect of glucocorticoids[J]. J Neural Transm Gen Sect, 1991,84 (1/2): 3-18.
[4] Majewski HK, Musgrave IF. Second messenger pathways in themodulation of neurotransmitter release[J]. AustN Z J Med, 1995,25(6): 817-821.
[5] Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling[J]. J Recept Signal Transduct Res, 2004,24(3): 165-205.
[6] Teng FY, Tang BL. Axonal regeneration in adult CNS neurons-signaling molecules and pathways[J]. J Neurochem,2006, 96(6):1501-1508.
[7] Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target[J]. Drug Discov Today,2005, 10(22): 1503-1519.
[8] Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling[J]. Annu Rev Biochem,2007,76(3): 481-511.
[9] Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use[J]. Pharmacol Rev, 2006, 58(3): 488-520.
[10] Esposito K, Reierson GW, Luo HR, et al. Phosphodiesterase genes and antidepressant treatment response: a review[J]. Ann Med, 2009, 41(11): 177-185.
[11] Jager R, Schwede F, Genieser HG, et al. Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5[J]. Br J Pharmacol,2010,12(13): 123-132.
[12] Pandit J, Forman MD, Fennell KF, et al. Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct[J]. PNAS,2009, 106(43): 18225-18230.
[13] Aravind L, Ponting CP. The GAF domain: an evolutionary link between diverse phototransducing proteins[J]. Trends Biochem Sci ,1997,22: 458-459.
[14] Kleppisch T. Phosphodiesterases in the central nervous system[J]. Handb Exp Pharmacol, 2009,12(191): 71-92.
[15] Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use[J]. Pharmacol Rev,2006, 58(3): 488-520.
[16] Boess FG, Hendrix M, van der Staay FJ, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance[J]. Neuropharmacology, 2004, 47(7): 1081-1092.
[17] Blokland R, Schreiber R, Prickaerts J. Improving memory: a role for phosphodiesterases[J]. Curr Pharm Des,2006, 12(2): 2511-2523.
[18] Tsai LC, Beavo JA. The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis[J].Curr Opin Pharmacol, 2011,11(6):670-675.
[19] Pollatos O, Kopietz R, Linn J, et al. Emotional stimulation alters olfactory sensitivity and odor judgment[J]. Chem Senses, 2007, 32(6): 583-589.
[20] Drobna E, Gazdag Z, Culakova H, et al. Overexpression of the YAP1, PDE2, and STB3 genes enhances the tolerance of yeast to oxidative stress induced by 7-chlorotetrazolo[5,1-c] benzo[1,2,4] triazine[J].FEMS Yeast Res, 2012, 12(8):958-968.
[21] Suvarna NU, O'Donnell JM. Hydrolysis of N-Methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus[J]. J Pharmacol Exp Ther, 2002, 302(4): 249-256.
[22] Masood A, Huang Y, Hajjhussein H, et al. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling[J]. J Pharmacol Exp Ther, 2009, 331(2): 690-699.
[23] Pelligrino DA, Wang Q. Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation[J]. Prog Neurobiol,1998, 56(7): 1-18.
[24] Heine C, Sygnecka K, Scherf N, et al. Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures[J]. Neurosignals, 2013,21(3/4):197-212.
[25] Deng C, Wang D, Bugaj-Gaweda B, et al. Assays for cyclic nucleotide-specific phosphodiesterases (PDEs) in the central nervous system (PDE1, PDE2, PDE4, and PDE10)[J]. Curr Protoc Neurosci, 2007, 7(2): 7-21.
[26] Boess FG, Hendrix M, van der Staay FJ, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance[J]. Neuropharmacology, 2004,47(7):1081-1092.
[27] Sierksma AS, Rutten K, Sydlik S, et al. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease[J]. Neuropharmacology,2013, 64:124-136.
[28] O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)[J]. Trends Pharmacol Sci, 2004, 25(3): 158-163.
[29] Pérez-Torres S, Miró X, Palacios JM, et al. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H] rolipram binding autoradiography. Comparison with monkey and rat brain[J]. J Chem Neuroanat, 2000, 20(3/4): 349-374.
[30] Reneerkens OA, Rutten K, Bollen E, et al. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801[J]. Behav Brain Res, 2013, 236(1):16-22.
[31] Masood A, Nadeem A, Mustafa SJ, et al. Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice[J]. J Pharmacol Exp Ther, 2008, 326(2): 369-379.
[32] Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: adynamic duo in age-related neuronal plasticity andneurodegenerative disorders[J]. Trends Neurosci, 2004,27(3), 589-594.
[33] Banasr M, Hery M, Printemps R, et al. Serotonin-induced increases in adult cell proliferation andneurogenesis are mediated through different and common5-HT receptor subtypes in the dentate gryus and thesubventricular zone[J].Neuropsychopharmacology, 2004, 29(3):450-460.
[34] Yuasa K, Kanoh Y, Okumura K, et al. Genomic organization of the human phosphodiesterase PDE11A gene, Evolutionary relatedness with other PDEs containing GAF domains[J]. Eur J Biochem, 2001, 268(1): 168-178.
[35] Bon CL, Garthwaite J. On the role of nitric oxide in hippocampal long-term potentiation[J]. J Neurosci, 2003,23(1): 1941-1948.
[36] Zhang HT, Huang Y, Jin SL, et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme[J]. Neuropsychopharmacology, 2002, 27(4): 587-595.
[37] Zhang HT, Zhao Y, Huang Y, et al. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus[J]. Neuropsychopharmacology, 2004, 29(8):1432-1439.
[38] Zhang HT, Huang Y, Suvarna NU, et al. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats[J]. Psychopharmacology, 2005, 179(3): 613-619.
[39] Pickard BS, Thomson PA, Christoforou A, et al. The PDE4B gene confers sex-specific protection against schizophrenia[J]. Psychiatr Genet, 2007, 17(3):129-133.
[40] Pilz RB, Broderick KE. Role of cyclic GMP in gene regulation[J]. Front Biosci, 2005, 10: 1239-1268.